Individual in-vitro dissolving and detecting method and dissolving device of active ingredient of pharmaceutic preparation
An active ingredient, in vitro dissolution technology, applied in the direction of testing pharmaceutical preparations, material inspection products, etc., can solve the problems of not considering drug exposure, inconsistent actual conditions, inconsistent completion of dissolution conditions, etc.
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0043] Study on the new method of in vitro dissolution of levamlodipine besylate tablets and the correlation study in vivo and in vitro
[0044] (1) In vitro dissolution method research
[0045] 1 Drugs, reagents and instruments
[0046] 1.1 Drugs
[0047] Levoamlodipine besylate tablets: Anhui Star Pharmaceutical Co., Ltd. (batch number 1112132.5mg), Shihuida Pharmaceutical Group (Jilin) Co., Ltd. (batch number 120102 25mg), Guizhou Liansheng Pharmaceutical Co., Ltd. (batch number 1112012.5mg), Nanchang Hong Yi Pharmaceutical Co., Ltd. (batch number 111205 2.5 mg).
[0048] 1.2 Reagents
[0049] Self-made deionized ultrapure water, chemical reference substance of levamlodipine besylate (National Inspection Institute), and other reagents are of analytical grade.
[0050] 1.3 Instruments
[0051] DZG-303A laboratory pure water system (Aike. Chongqing Yixiang Development Co., Ltd.); UV-visible spectrophotometer (SHIMAZU); METTLER TOLEDO AB135-S 1 / 100,000 balance (METTLER,...
Embodiment 2
[0187] Example 2: Research on new method of in vitro dissolution of lamivudine tablets and correlation research in vivo and in vitro
[0188] (1) In vitro dissolution method research
[0189] Except that the medicine and the reference substance are different, other reagents and methods are the same as in Example 1, and the research results are as follows: Figure 11~Figure 13 and Tables 17, 18. Lamivudine tablets: GlaxoSmithKline Pharmaceuticals (Suzhou) Co., Ltd. (batch number 11070033100mg)
[0190] Table 17 Differential dissolution of Lamivudine tablets of GlaxoSmithKline (Suzhou) Co., Ltd.
[0191]
[0192]
[0193] continued
[0194]
[0195] continued
[0196]
[0197] (2) Dissolution study of lamivudine tablets in vivo
[0198] Except that the drug and the reference substance are different, other reagents, research methods, and experimental design are similar to Example 1, and will not be reported in detail. Selected results of the study are reported b...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 